ConvaTec (CTEC.L): Key Takeaways from the 2026 CEO Call

On 6 October 2026, J.P. Morgan hosted a Conference Call with ConvaTec CEO Jonny Mason as part of its 2026 CEO Conference Call Series. Management expressed confidence in 2027 and mid-term numbers, reiterating the "Accelerate" framework: 6-8% organic revenue growth from next year, reaching mid-20s operating margins next year (defined as 24-26%) and then holding in-range while reinvesting operating leverage to sustain growth and deliver ongoing double-digit EPS growth. Acceleration is expected to be broad-based across all four divisions, supported by category-specific launches including Natura Body (ostomy), GC Air Pocket and Set (continence), multiple advanced wound care launches alongside the removal of the InnovaMatrix headwind, and continued strength in infusion care. Margin drivers include continued scope to reduce G&A (targeting c5% of sales), improving factory automation (3 of 5 large factories automated so far), and positive mix. Management spoke about a materially accelerated pip